Recent News and Articles on the Keywords: new + breast + cancer  Related to the article below (Last Update: 8/7/2008)

Clarient and Health Discovery Corporation Announce Results from ... Business Wire (press release), CA - Physicians who are diagnosing and treating prostate cancer patients should be greatly assisted by the additional information that this new prostate cancer ... Clarient Reports Second Quarter Revenue Up 71% Trading Markets (press release) all 21 news articles »  CLRT - OTC:HDVY Ottawa Citizen Young Women May Be Underrepresented In Breast Cancer Research ... Medical News Today (press release), UK - While the incidence of breast cancer in young women in the US is relatively rare, there are more than 250000 women under the age of forty that are living ... AssociatedPress HealthWatch: Applegate's Cancer Serves As Reminder WCBS-TV New York Christina Applegate Diagnosed with Early Form of Breast Cancer Associated Content The Associated Press - ChattahBox all 1,012 news articles » Los Angeles Times Sex After Breast Cancer U.S. News & World Report, DC - Aug 5, 2008 Yesterday I discussed Christina Applegate's diagnosis of breast cancer, and hundreds of reports on that news have been teeming with information?from the way ... Breast cancer diagnosis ... and the outcome Los Angeles Times Breast cancer: What you need to know Food Consumer The emotional side of breast cancer and its treatments Gather.com FOXNews all 6 news articles » deCODE genetics Announces Second Quarter 2008 Financial Results MarketWatch - Diagnostics: Breast cancer. In the second quarter deCODE discovered a fourth set of common single-letter variants (SNPs) associated with risk of estrogen ...DCGN Chemokine Therapeutics Announces Breast Cancer Data Presented at a ... Market Wire (press release) - The data demonstrated in pre-clinical models that CTCE-9908 decreased the spread of breast cancer to the ovary by about half, decreased the size of tumors ...TSE:CTI Study Suggests Bone Mineral Density May Indicate Breast Cancer Risk DOTmed.com (press release), NY - by Astrid Fiano, Writer A new study in the September issue of CANCER, the journal of the American Cancer Society, suggests that measuring a woman's bone ... Chemokine Therapeutics Announces Breast Cancer Data Presented at a ... MarketWatch - The data demonstrated in pre-clinical models that CTCE-9908 decreased the spread of breast cancer to the ovary by about half, decreased the size of tumors ...TSE:CTI - OTC:CMTX OverTheLimit.info Health Buzz: New Flu Vaccines and Other Health News U.S. News & World Report, DC - While much attention is paid to breast cancer diagnosis and treatment, a side effect that is rarely discussed is how tough it is for breast cancer patients ... Novartis begins shipment to US of Fluvirin(R) Influenza Virus ... Trading Markets (press release) all 68 news articles »  NVS - BOM:500672 - OTC:CMTX 3 News NZ PHARMAC reaffirms confidence in 9 week Herceptin treatment Scoop.co.nz (press release), New Zealand - New Zealanders continue to have fully funded access to an effective and full course of Herceptin treatment for HER2-positive early breast cancer ... A thorn in Pharmac's side Stuff.co.nz Pharmac decides not to fund year-long Herceptin course New Zealand Herald Herceptin decision a 'cruel blow' The Dominion Post Gay NZ - Stuff.co.nz all 38 news articles » CTV.ca Prostate cancer rate spurs campaigners So Md News, MD - The county health department in White Plains offers prostate, colorectal, cervical and breast cancer screenings, said Chinnadurai Devadason, the county?s ... Routine prostate screens 'premature' The Age Cancer hits men's minds Macarthur Advertiser Over 75? Skip the Prostate Cancer Screening, Say Experts findingDulcinea New York Times - WTVH all 769 news articles »

Non-BRCA hereditary breast cancer linked to new cancers

The risk for a new cancer in the unaffected breast substantially increases in women diagnosed with unilateral, hereditary ( non-BRCA ) breast cancer.

A study reveals women under 50 diagnosed with hereditary ( non-BRCA ) breast cancer are at significantly greater risk for developing cancer in the other breast, also known as contralateral breast cancer ( CBC ).
Adjuvant hormonal therapy, however, reduces contralateral breast cancer risk.

Women with hereditary ( non-BRCA ) breast cancer are estimated to be at up to six times greater risk of developing a second primary malignancy in the other breast than the general population is of developing primary breast cancer.
Young age at first diagnosis, family history of breast cancer, and confirmed BRCA1 or BRCA2 gene mutations are the primary risk factors for contralateral breast cancer .
However, the contribution of non-BRCA hereditary cancers to the risk of contralateral breast cancers is poorly understood.

Led by Katarina Shahedi, of the Umeå University and colleagues at the Karolinska Institute in Stockholm, Sweden, researchers reviewed data from 120 families and 204 women with unilateral breast cancer and a family history of breast cancer but no BRCA mutations to better characterize the contralateral breast cancer risk for these women.

They found that the long term contralateral breast cancer risk was significantly higher in women with hereditary breast cancer compared to the risk of developing a primary breast cancer in the general population.
The overall probability for these women was 5.5 percent at 5 years and up to 27.3 percent at 20 years compared to only 1.9 percent at 5 years and 4.9 percent at 20 years for the general population. Further analysis by age group showed clearly that the 15 year probability of developing a contralateral breast cancer was significantly elevated for women under 50 years old compared to women over 50 years old ( 40 percent and 10 percent, respectively ).

Women who took adjuvant hormonal therapy had significantly lowered risk for a contralateral breast cancer compared to those who did not take it.
Adjuvant chemotherapy had no apparent effect on risk.

In the first published study to characterize contralateral breast cancer risk in non-BRCA hereditary breast cancers, the authors demonstrate " that women with hereditary/familial non-BRCA1/BRCA2 breast cancer have a very high risk of developing contralateral breast cancer."

The impact of these results is most apparent for premenopausal women, in who 1 in 5 will develop contralateral breast cancer after only 10 years.

Source: Cancer, 2006